ArticleCancer discovery2018
A Preexisting Rare
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 93 citations in OpenAlex.
- Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.PloS one · 2021Trial
- Anchored random reverse primer sequencing for quantitative detection of novel gene fusions.Nature biomedical engineering · 2026Article
- FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma.Cell death discovery · 2026Article
- Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors.Pharmacological research · 2025Review
- In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.Journal of experimental & clinical cancer research : CR · 2025Article
- Review
- Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistantScience translational medicine · 2025Article
- Epithelial and macrophage cell interaction in cervical cancer through single-cell RNA-sequencing and spatial analysis.Frontiers in immunology · 2025Article
- Melanoma genomics - will we go beyond BRAF in clinics?Journal of cancer research and clinical oncology · 2024Review
- A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.Communications biology · 2024Article
- The future of targeted kinase inhibitors in melanoma.Pharmacology & therapeutics · 2022Review
- Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Cancer research · 2022Article
- S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.Molecular cancer · 2022Article
- Review
- Heterogeneity in Melanoma.Cancers · 2022Review
- Targeting CDK4 and CDK6 in cancer.Nature reviews. Cancer · 2022Review
- Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.Cancers · 2022Review
- Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.Nature biomedical engineering · 2022Review
- CDK4 and CDK6 kinases: From basic science to cancer therapy.Science (New York, N.Y.) · 2022Review
- Functionalization of Nanomaterials for Skin Cancer Theranostics.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 2 institutions in 1 country.
Gabriele RomanoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pei-Ling ChenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ping SongDepartment of Bioengineering, Rice University, Houston, Texas.
Jennifer L McQuadeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Roger J LiangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mingguang LiuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Whijae RohDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Dzifa Y DuoseDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fernando C L CarapetoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jun LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jessica L F TehDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Andrew E AplinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Merry ChenDepartment of Neurooncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael A DaviesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rodabe N AmariaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David Y ZhangDepartment of Bioengineering, Rice University, Houston, Texas.
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. lkwong@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USRice University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3MRequest for Supplemental Funds aligned to CA160495R01CA160495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2012 to 2022
$3.6MTargeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4MHighly multiplexed and mutation-sensitive quantitative PCR for cancer diagnosticsR01CA203964 · NCI · RICE UNIVERSITY · PI ZHANG, DAVID YU · 2016 to 2020
$3.0MNCI NIH HHS P01 CA163222NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA160495NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA203964
Abstract
Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with
Indexed as
MutationSignal TransductionAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCell Line, TumorClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmFemaleGTP PhosphohydrolasesHumansMelanomaMembrane ProteinsMiceBiomarkersCDK4 protein, humanCDK6 protein, humanClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6GTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanPIK3CA protein, humanProtein Kinase Inhibitorsribosomal protein S6 kinase, 70kD, polypeptide 1Ribosomal Protein S6 Kinases, 70-kDa
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.